Results 11 to 20 of about 62,912 (312)

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

New England Journal of Medicine, 2021
Background The efficacy and safety of tofacitinib, a Janus kinase inhibitor, in patients who are hospitalized with coronavirus disease 2019 (Covid-19) pneumonia are unclear.
Patrícia O. Guimarães, D. Quirk, R. Furtado, L. Maia, J. Saraiva, M. Antunes, R. Kalil Filho, V. M. Junior, A. Soeiro, A. Tognon, V. Veiga, P. A. Martins, D. Moia, Bruna S Sampaio, S. R. L. Assis, R. V. P. Soares, L. P. A. Piano, K. Castilho, Roberta G. R. A. P. Momesso, Frederico Monfardini, H. Guimarães, D. Ponce de Leon, Majori Dulcine, Marcia Pinheiro, L. M. Gunay, J. Deuring, L. Rizzo, T. Koncz, O. Berwanger   +28 more
semanticscholar   +1 more source

Tofacitinib Suppresses Natural Killer Cells In Vitro and In Vivo: Implications for Amyotrophic Lateral Sclerosis

Frontiers in Immunology, 2022
Amyotrophic lateral sclerosis (ALS) is a fatal and incurable neurodegenerative disease with few therapeutic options. However, the immune system, including natural killer (NK) cells, is linked to ALS progression and may constitute a viable therapeutic ALS
Claudia Figueroa-Romero, Alina Monteagudo, Benjamin J. Murdock, Joshua P. Famie, Ian F. Webber-Davis, Caroline E. Piecuch, Samuel J. Teener, Crystal Pacut, Stephen A. Goutman, Eva L. Feldman   +9 more
doaj   +1 more source

Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance

Annals of the Rheumatic Diseases, 2023
Objectives Based on primary results from ORAL Surveillance, an event-driven clinical trial of risk-enriched patients, identify subpopulations with different relative risk (ie, ‘high-risk’ and ‘low-risk’) with tofacitinib versus tumour necrosis factor ...
L. Kristensen, S. Danese, A. Yndestad, Cunshan Wang, E. Nagy, I. Modesto, J. Rivas, B. Benda   +7 more
semanticscholar   +1 more source

Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis

BMC Gastroenterology, 2022
Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. We aimed to describe the real-world treatment experience and corticosteroid utilisation of patients treated with tofacitinib in a US claims database.
Michael V. Chiorean, Jessica R. Allegretti, Puza P. Sharma, Benjamin Chastek, Leonardo Salese, Elizabeth J. Bell, Jesse Peterson-Brandt, Joseph C. Cappelleri, Xiang Guo, Nabeel Khan   +9 more
doaj   +1 more source

Fracture in clinical studies of tofacitinib in rheumatoid arthritis

Therapeutic Advances in Musculoskeletal Disease, 2022
Background: Preclinical data suggest that tofacitinib would protect bone health in patients with rheumatoid arthritis (RA). Objective: To assess fracture risk in tofacitinib RA clinical trials. Design: Post hoc analysis.
Karen E. Hansen, Mahta Mortezavi, Edward Nagy, Cunshan Wang, Carol A. Connell, Zaher Radi, Heather J. Litman, Giovanni Adami, Maurizio Rossini   +8 more
doaj   +1 more source

Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing [PDF]

, 2020
Both inflammatory diseases like rheumatoid arthritis (RA) and anti-inflammatory treatment of RA with glucocorticoids (GCs) or non-steroidal anti-inflammatory drugs (NSAIDs) negatively influence bone metabolism and fracture healing.
Brinkman, Antonia Clara Katharina, Burmester, Gerd-Rüdiger, Buttgereit, Frank, Damerau, Alexandra, Diesing, Karoline, Gaber, Timo, Hoff, Paula, Lang, Annemarie, Ohrndorf, Sarah, Pfeiffenberger, Moritz, Pienczikowski, Justyna   +10 more
core   +1 more source

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

Annals of the Rheumatic Diseases, 2022
Objectives Evaluate risk of major adverse cardiovascular events (MACE) with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) with or without a history of atherosclerotic cardiovascular disease (ASCVD)
C. Charles-Schoeman, M. Buch, M. Dougados, Deepak L. Bhatt, J. Giles, S. Ytterberg, G. Koch, I. Vranic, Joseph Wu, Cunshan Wang, K. Kwok, S. Menon, J. Rivas, A. Yndestad, C. Connell, Z. Szekanecz   +15 more
semanticscholar   +1 more source

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib

Annals of the Rheumatic Diseases, 2021
Objective Janus kinase inhibitors (JAKinibs) are efficacious in rheumatoid arthritis (RA) with variable reported rates of adverse events, potentially related to differential JAK family member selectivity.
Paqui G Través, B. Murray, F. Campigotto, R. Galien, A. Meng, J. D. Di Paolo   +5 more
semanticscholar   +1 more source

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study

Annals of the Rheumatic Diseases, 2021
Objective To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing spondylitis (AS). Methods This phase III, randomised, double-blind, placebo-controlled study enrolled patients aged ≥18 years diagnosed with active AS ...
A. Deodhar, P. Śliwińska-Stańczyk, Huji Xu, X. Baraliakos, L. Gensler, D. Fleishaker, Lisy Wang, Joseph Wu, S. Menon, Cunshan Wang, O. Dina, L. Fallon, K. Kanik, D. M. van der Heijde   +13 more
semanticscholar   +1 more source

Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore

BMC Gastroenterology, 2023
Background Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We evaluated tofacitinib efficacy and safety in the 52-week maintenance study, OCTAVE Sustain, by baseline Mayo endoscopic subscore (MES ...
Scott D. Lee, Jessica R. Allegretti, Flavio Steinwurz, Susan B. Connelly, Nervin Lawendy, Jerome Paulissen, Krisztina B. Gecse   +6 more
doaj   +1 more source